Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators after showing ...
Roche annonce que la FDA des États-Unis a accordé un examen prioritaire à son inévolib, en association avec le palbociclib et le fulvestrant, pour le - 29/05/2024 09:12 ...
The US Food and Drug Administration (FDA) has granted Roche a breakthrough therapy designation for its breast cancer therapy inavolisib, based on positive results from its recent Phase III trial.
By Pierre Bertrand Roche said that the U.S. Food and Drug Administration has designated its Inavolisib breast cancer treatment as a breakthrough therapy.
Swiss drug major Roche Holding AG (RHHBY) and its U.S. Unit Genentech announced Tuesday that the U.S. Food and Drug Administration ...
J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY) and Roche's (RHHBY) regulatory applications.
Roche RHHBY obtained a Breakthrough Therapy Designation for its investigational oral therapy inavolisib for treating adult breast cancer patients in the United States. The FDA granted this designation ...
Patients without disease progression following chemoradiotherapy for unresectable stage III non-small cell lung cancer (NSCLC ...